April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
In vitro Evaluation of N,N-dichloro-2,2-dimethyltaurine (AL-46383A) as an Antiviral Agent Against Adenovirus and HSV-1
Author Affiliations & Notes
  • E. G. Romanowski
    The Charles T. Campbell Lab, University of Pittsburgh, Pittsburgh, Pennsylvania
  • K. A. Yates
    The Charles T. Campbell Lab, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Y. J. Gordon
    The Charles T. Campbell Lab, University of Pittsburgh, Pittsburgh, Pennsylvania
  • D. W. Stroman
    Alcon Research Ltd, Fort Worth, Texas
  • Footnotes
    Commercial Relationships  E.G. Romanowski, Alcon, F; Alcon, C; K.A. Yates, Alcon, F; Y.J. Gordon, Alcon, F; Alcon, C; D.W. Stroman, Alcon, E.
  • Footnotes
    Support  Alcon Research Ltd., NIH Core Grant EY08098, RPB, Eye & Ear Foundation
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2434. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. G. Romanowski, K. A. Yates, Y. J. Gordon, D. W. Stroman; In vitro Evaluation of N,N-dichloro-2,2-dimethyltaurine (AL-46383A) as an Antiviral Agent Against Adenovirus and HSV-1. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2434.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The goal of the current study was to evaluate the in vitro efficacy of N,N-dichloro-2,2-dimethyltaurine (AL-46383A [AL]), a stable derivative of dichlorotaurine that represents a new class of broad spectrum antimicrobials (Aganocides), against ocular isolates of adenovirus (Ad) and HSV-1.

Methods: : In duplicate trials, the direct inactivating activity of AL-46383A was determined by incubating high titer stocks of clinical isolates of Ad1, Ad2, Ad3, Ad4, Ad5, Ad7, Ad8, Ad19, Ad37 ATCC, and HSV-1 with 0.9%, 0.1%, 0.01%, and 0.001% AL-46383A and control media for 60 minutes at room temp. Standard plaque assays were performed on the reaction mixtures to determine the viral titers after AL-46383A or control treatment. Viral titers were Log10 converted and Log10 reductions in titers from the control were calculated and expressed as the mean ± sd Log10 Reduction in titer.

Results: : Log10 Reductions in Titers (PFU/ml)Virus___0.9% AL___0.1% AL___0.01% AL__0.001% ALAd1____3.35±0.49__1.11±0.15__1.50±0.59__1.30±0.20Ad2____2.49±0.15__1.27±0.92__1.34±0.16__1.04±0.39Ad3____4.00±0.19__2.48±0.46__1.24±0.05__1.27±0.37Ad4____5.19±0.24__1.28±0.09__1.74±0.51__2.09±0.59Ad5____4.89±0.30__2.53±0.76__1.97±1.41__1.07±0.32Ad7____3.95±0.13__2.23±1.68__1.64±1.26__1.37±0.84Ad8____3.00±0.83__2.51±0.42__1.37±1.00__1.59±0.76Ad19___4.34±2.46__3.01±0.16__3.40±0.29__2.56±0.68Ad37___4.81±0.56__2.84±0.04__2.33±0.33__1.53±0.35HSV-1__4.66±0.77__3.11±1.42__1.86±0.15__1.35±0.35

Conclusions: : AL-46383A demonstrated direct inactivation of all ocular viral isolates at all concentrations tested. All AL-46383A concentrations demonstrated at least a 1-Log10 reduction in the mean titers of all viral isolates. Further study of AL-46383A in animal ocular models of Ad and HSV-1 infections is warranted.

Keywords: adenovirus • herpes simplex virus • antiviral drugs 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×